A__O new__O generation__O of__O biocompatible__O fluids,__O developed__O from__O Cardiff__B-LOC discoveries,__O is__O now__O delivering__O impacts__O worldwide__O including:__O Patient__O health__O &#8212;__B-ORG Worldwide__I-ORG reduction__O in__O mortality__O and__O the__O likelihood__O and__O severity__O of__O infection.__O
New__O therapies__O &#8212;__B-ORG The__I-ORG Cardiff__I-ORG method__O is__O internationally__O accepted__O for__O evaluating__O new__O PD__B-ORG therapies.__O
Improved__O practice__O &#8212;__O International__O guidelines__O recommend__O nephrologists__O use__O new__O PD__B-ORG solutions.__O
Economic__O benefit__O &#8212;__O Biocompatible__O fluids__O are__O replacing__O older__O solutions__O in__O a__O $1.7billion__O p.a.__O
market__O Healthcare__O cost__O benefit__O &#8212;__B-ORG Reduced__I-ORG hospital__O stays__O and__O lower__O peritonitis__O treatment__O costs.__O
Background:__B-ORG Advances__I-ORG originating__O in__O Cardiff__B-LOC lead__O to__O biocompatible__O PD__O fluid__O development__O The__O novel__O discoveries__O and__O testing__O methods__O developed__O in__O Cardiff__B-LOC made__O key__O advances__O that__O drove__O and__O enabled__O new__O biocompatible__O solution__O development.__O
Test__O systems__O developed__O in__O Cardiff__B-LOC established__O that__O the__O combination__O of__O low__O pH__O and__O high__O lactate__O concentrations__O inhibited__O host__O defence__O and__O cell__O viability__O and__O established__O the__O cellular__O mechanisms__O responsible__O for__O the__O negative__O impact__O of__O high__O glucose__O concentrations.__O
This__O research__O led__O directly__O to__O the__O production__O of__O physiological__O pH__O PD__O solutions,__O e.g.__O
Physioneal&#174;__O (Baxter),__O Balance&#174;__O (Fresenius),__O and__O the__O use__O of__O lower__O lactate__O concentrations__O by__O replacement__O with__O bicarbonate__O in__O commercial__O solutions,__O e.g.__O
Physioneal&#174;,__B-ORG Bicavera&#174;__I-ORG (Fresenius).__I-ORG
Identification__O of__O the__O negative__O consequences__O of__O high__O glucose__O concentrations__O and__O osmolality__O led__O directly__O to__O the__O implementation__O of__O glucose__O sparing__O therapies__O using__O glucose__O polymer&#8212;__O and__O amino__O acid-based__O solutions__O such__O as__O Extraneal&#174;__B-ORG and__O Nutrineal&#174;__B-ORG (Baxter)__I-ORG [5.1]__O in__O which__O Cardiff__B-LOC also__O played__O a__O leading__O role__O in__O pre-clinical__O development.__O
Cardiff__B-LOC contributed__O to__O the__O establishment__O of__O glucose__O degradation__O product__O research__O that__O underpins__O new__O PD__B-ORG solution__O design__O (Physioneal&#174;,__B-ORG Balance&#174;__I-ORG and__O Trio&#174;).__B-LOC
This__O body__O of__O work__O was__O critical__O to__O establishing__O a__O new__O field__O of__O PD__B-MISC solutions__O research,__O and__O led__O directly__O to__O the__O iterative__O development__O of__O new__O products__O in__O which__O Cardiff__B-LOC played__O a__O direct__O role__O [5.2-5.4],__O for__O example__O "The__O critical__O contribution__O of__O Prof__B-ORG Nick__I-ORG Topley's__I-ORG research__O group__O at__O Cardiff__B-ORG University__I-ORG in__O the__O development__O phase__O of__O the__O PD__O solutions__O Physioneal__O 35__O and__O 40"__O (Professor__O Peter__B-PER Rutherford,__I-PER Medical__O Director__O (Renal)__B-PER &#8212;__O Europe,__B-PER Middle__I-PER East__I-PER and__O Africa__B-ORG Baxter__I-ORG Healthcare__I-ORG SA__I-ORG [5.2]).__O
Williams,__B-PER Coles__I-PER and__O Topley__O acted__O as__O scientific__O advisors__O to__O Baxter__B-ORG and__O Fresenius__B-MISC (the__O leading__O PD__B-ORG solution__O manufacturers__O worldwide),__O guiding__O them__O in__O the__O composition__O of__O new__O solutions__O to__O reduce__O their__O detrimental__O effects__O and__O in__O the__O design__O of__O relevant__O clinical__O trials__O [3.5,3.6].__O
The__O biocompatibility__O and__O clinical__O trial__O data__O from__O Cardiff__B-LOC was__O used__O for__O the__O worldwide__O registration__O of__O Physioneal__B-ORG [5.2]__I-ORG and__O in__O all__O (including__O current)__O regulatory__O submissions__O for__O new__O PD__B-ORG solutions__O by__O Fresenius__B-ORG [5.3].__O
Professor__O Simon__B-PER Davies,__I-PER who__O runs__O the__O largest__O PD__B-ORG unit__O in__O the__O UK__B-LOC and__O is__O one__O of__O the__O foremost__O authorities__O on__O PD,__O dedicated__O in__O 2011__O an__O international__O journal__O publication__O to__O the__O Cardiff's__B-ORG team__O contribution__O to__O PD__B-ORG research.__O
Amongst__O many__O testaments__O to__O Cardiff's__B-LOC leading__O transformational__O research__O in__O this__O area__O the__O article__O states:__O "The__O hallmark__O of__O the__O Cardiff__B-LOC contribution__O to__O our__O understanding__O of__O PD__B-ORG has__O been__O their__O translational__O approach__O to__O research,__O combining__O strong__O basic__O science__O with__O intelligent__O clinical__O questions...resulting__O in__O the__O development__O and__O testing__O of__O more__O biocompatible__O solutions.__O
More__O than__O any__O other__O group,__O they__O have__O held__O the__O torch__O for__O basic__O science__O in__O PD__O research.__O
These__O observations__O led__O to__O the__O conceptualization__O of__O biocompatibility__O as__O a__O local__O intraperitoneal__O process__O distinct__O from__O the__O systemic__O effects__O of__O PD...and__B-MISC became__O the__O gold__O standard__O approach__O to__O assessing__O the__O biocompatibility__O of__O newly__O developed__O PD__B-ORG solutions"__O [5.4].__O
Biocompatible__O PD__O fluids__O improve__O patient__O outcomes__O and__O quality__O of__O life__O Following__O early__O clinical__O trial__O work__O by__O Cardiff,__B-ORG independent__O studies__O from__O other__O centres__O have__O provided__O endorsement__O of__O the__O benefits__O of__O biocompatible__O fluids,__O and__O data__O continues__O to__O accrue__O in__O this__O area.__O
In__O 2012__O a__O randomised__O study__O in__O Australia__B-LOC and__O New__B-LOC Zealand__I-LOC compared__O conventional__O and__O biocompatible__O PD__O therapy__O in__O patients__O for__O two__O years__O and__O observed__O a__O 40%__O reduction__O in__O peritonitis__O rates.__O
When__O infection__O did__O occur__O it__O was__O more__O likely__O to__O be__O classed__O as__O mild,__O and__O the__O length__O of__O stay__O in__O hospital__O was__O halved__O from__O 11__O to__O 6__O days__O [5.5,5.6].__O
In__O 2012,__O an__O observational__O study__O of__O 2163__O patients__O in__O Korea__B-LOC noted__O a__O 30%__O reduction__O in__O all-cause__O mortality__O in__O patients__O using__O biocompatible__O solutions__O compared__O to__O a__O cohort__O using__O conventional__O fluids.__O
The__O absolute__O risk__O of__O death__O per__O year__O in__O this__O study__O was__O 5.93%__O in__O the__O group__O treated__O with__O biocompatible__O solutions__O and__O 8.86%__O in__O those__O treated__O with__O standard__O therapy,__O suggesting__O that__O one__O life__O may__O be__O saved__O per__O year__O for__O each__O 38__O patients__O treated__O with__O biocompatible__O fluid__O [5.7].__O
Biocompatible__O fluids__O are__O recommended__O in__O clinical__O guidelines__O The__O growing__O recognition__O of__O the__O benefits__O of__O biocompatible__O PD__O solutions__O is__O highlighted__O by__O the__O 2011__O publication__O of__O the__O European__B-ORG Paediatric__I-ORG Dialysis__I-ORG Working__I-ORG Group__I-ORG Guidelines__I-ORG [5.8].__O
The__O document,__O distributed__O to__O over__O 800__O paediatric__O nephrologists__O worldwide,__O advises__O that__O biocompatible__O solutions__O with__O the__O lowest__O possible__O glucose__O concentration__O should__O be__O used__O in__O all__O childhood__O patients.__O
The__O guidelines__O also__O state__O that__O solutions__O formulated__O to__O reduce__O glucose__O degradation__O and__O with__O bicarbonate__O as__O a__O buffer__O should__O be__O used__O to__O reduce__O systemic__O toxicity.__O
Development__O of__O biocompatible__O fluids__O has__O had__O economic__O impact__O The__O peritoneal__O dialysis__O (PD)__O market__O was__O valued__O at__O $1.7__O billion__O in__O 2008__O and__O is__O expected__O to__O grow__O at__O 7%__O per__O annum__O to__O reach__O $2.9__O billion__O in__O 2015__O [5.9].__O
Biocompatible__O PD__O solutions__O are__O currently__O available__O worldwide__O for__O clinical__O use__O [5.2,5.3].__O
Marketing__O authorisations__O have__O been__O granted__O in__O territories__O including__O Europe,__B-ORG North__I-ORG America__I-ORG and__O Australasia__B-ORG and__O are__O currently__O being__O sought__O in__O many__O other__O countries.__O
The__O Cardiff__B-LOC research__O and__O clinical__O trials__O provided__O key__O data__O for__O the__O worldwide__O registration__O and__O marketing__O authorisation__O for__O new__O biocompatible__O PD__B-ORG fluids__O [5.2,5.3]__O with__O the__O prescribing__O of__O biocompatible__O PD__B-ORG fluids__O increasing__O year__O on__O year.__O
In__O 2010,__O across__O 17__O European__B-MISC countries__O 60%__O of__O all__O Baxter's__B-ORG PD__I-ORG fluids__O prescribed__O were__O biocompatible__O products,__O translating__O to__O 38.5__O million__O litres__O of__O Physioneal__B-ORG realising__O product__O sales__O of__O over__O &#163;100__O million.__O
In__O certain__O European__B-MISC countries,__O including__O Sweden,__B-PER Finland,__I-PER Norway__I-PER and__O Spain,__B-LOC biocompatible__O products__O have__O completely__O replaced__O standard__O glucose__O PD__B-ORG solutions__O and__O conventional__O fluids__O have__O been__O withdrawn__O [5.2].__O
Biocompatible__O fluids__O reduce__O healthcare__O costs__O The__O use__O of__O biocompatible__O PD__O solutions__O generates__O significant__O healthcare__O cost__O savings.__O
According__O to__O Kidney__B-ORG Health__I-ORG Australia,__I-ORG the__O average__O in-patient__O cost__O of__O treating__O PD-related__O peritonitis__O is__O ~AU$16-22K__B-MISC (~&#163;10-15K)__B-MISC for__O an__O average__O 11.5__O day__O admission.__O
The__O Johnson__B-PER studies__O [5.5,5.6]__O show__O that__O the__O use__O of__O biocompatible__O fluids__O halved__O the__O length__O of__O stay__O in__O hospitals__O to__O 6__O days.__O
With__O a__O rate__O of__O peritonitis__O hospitalisation__O at__O 1__O per__O 24__O patient-months__O of__O therapy__O cost__O savings__O of__O $50-75__O million__O p.a.__O
worldwide__O are__O possible__O if__O ~60%__O of__O patients__O were__O treated__O with__O biocompatible__O fluids.__O
In__O the__O UK,__B-MISC NICE__B-ORG estimates__O the__O costs__O associated__O with__O treating__O peritonitis__O exceed__O &#163;100__O million__O p.a.__O
A__O 40%__O reduction__O in__O peritonitis__O rates__O from__O the__O use__O of__O biocompatible__O solutions__O [5.6]__O would__O equate__O to__O a__O cost__O saving__O of__O &#163;24__O million__O p.a.__O
A__O robust__O methodology__O for__O measuring__O peritoneal__O membrane__O changes__O The__O highly__O cited__O (Section__B-ORG 2,__O [3.4])__O description__O of__O the__O stages__O of__O peritoneal__O fibrosis__O and__O vascular__O degeneration__O is__O now__O accepted__O internationally__O as__O the__O scoring__O system__O to__O grade__O the__O effects__O that__O modifications__O to__O PD__B-ORG therapy__O have__O on__O peritoneal__O membrane__O damage.__O
The__O methodology__O forms__O the__O basis__O of__O most__O comparative__O histopathologic__O studies__O of__O the__O peritoneal__O membrane__O in__O PD__O patients.__O
